Page last updated: 2024-11-13

cobra cardiotoxin proteins

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Cobra Cardiotoxin Proteins: Most abundant proteins in COBRA venom; basic polypeptides of 57 to 62 amino acids with four disulfide bonds and a molecular weight of less than 7000; causes skeletal and cardiac muscle contraction, interferes with neuromuscular and ganglionic transmission, depolarizes nerve, muscle and blood cell membranes, thus causing hemolysis. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID72201066
MeSH IDM0006549

Synonyms (10)

Synonym
cobra cardiotoxin proteins
cardiotoxin, cobra
cytotoxin d1 (naja naja atra)
cardiotoxin a3 (naja atra)
cardiotoxin iii (naja naja atra venom)
cardiotoxin ctx-iii (naja naja atra)
0qbh3y8m6j ,
cardiotoxin iii
11061-96-4
unii-0qbh3y8m6j

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" injection was noted, animal weight loss was negligible and there were no other signs of adverse toxicity."( VRCTC-310--a novel compound of purified animal toxins separates antitumor efficacy from neurotoxicity.
Etcheverry, MA; Johnson, J; Newman, RA; Vidal, JC; Viskatis, LJ,
)
0.13
" Serious adverse events are unusual following overdoses of first generation antihistamines although life-threatening adverse events have been described."( Safety of antihistamines in children.
Blumer, JL; Reed, MD; Ten Eick, AP, 2001
)
0.31

Pharmacokinetics

ExcerptReferenceRelevance
"A phase I study was performed to evaluate the maximum tolerated dose (MTD), safety profile and pharmacokinetic data with VRCTC-310, a natural product derived from purified snake venom fractions, with phospholipase A2 activity and inhibitory effects against human and murine tumor cell lines."( Phase I study of VRCTC-310, a purified phospholipase A2 purified from snake venom, in patients with refractory cancer: safety and pharmacokinetic data.
Araujo, CE; Cervellino, JC; Coni Molina, CM; Costa, LA; Diez, RA; Miles, HA, 1997
)
0.3

Dosage Studied

ExcerptRelevanceReference
" This preparation produced a dose-response curve in the presence of active cardiotoxin and demonstrated that cardiotoxin retained its biological activity after boiling, although cardiotoxin activity was destroyed by heating in the presence of dithiothreitol."( A bioassay for cobra cardiotoxin activity using semi-isolated cockroach heart.
Klowden, MJ; Trumble, MJ; Trumble, WR; Vitale, AJ; Wesson, CR, 1992
)
0.28
" The slope of the hemolysis dose-response curve was considerably steeper for halothane than for CTX."( Interactions in red blood cells between fatty acids and either snake venom cardiotoxin or halothane.
Beech, J; Fletcher, JE; Jiang, MS; Smith, LA; Tripolitis, L, 1990
)
0.28
" The increases in AST, ALT and LDH serum activities on days 2-4 were independent of dosing schedule and sharply decreased on day 8, despite continuation of treatment."( Toxicity of the novel animal-derived anticancer agent, VRCTC-310: acute and subchronic studies in beagle dogs.
DeTolla, LJ; Etcheverry, MA; Newman, RA; Russell, R; Stump, KC; Vidal, JG; Viskatis, LJ, 1995
)
0.29
" After phase I study in patients by intramuscular administration, the interest of intravenous (IV) dosing arose."( 30-day intravenous administration of VRCTC-310-ONCO in rabbits.
Arias, D; Costa, LA; Diez, RA; Martino, PE; Stanchi, NO, 2002
)
0.31
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (408)

TimeframeStudies, This Drug (%)All Drugs %
pre-199093 (22.79)18.7374
1990's125 (30.64)18.2507
2000's108 (26.47)29.6817
2010's71 (17.40)24.3611
2020's11 (2.70)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 8.44

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index8.44 (24.57)
Research Supply Index6.05 (2.92)
Research Growth Index4.49 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (8.44)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (0.72%)5.53%
Reviews13 (3.10%)6.00%
Case Studies2 (0.48%)4.05%
Observational0 (0.00%)0.25%
Other401 (95.70%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]